The Sponsor provided key assumptions from a recently outsourced study in an excel file. No protocol or study design was provided. The study was modeled as high complexity using Clinical Maestro's PORTFOLIO application for planning and budgeting. A preferred discount rate of 10% was applied. STUDY BUILD ASSESSMENT LARGE , HIGH -COMPLEXITY PHASE 2 /3 ONCOLOGY STUDY LEADING JAPANESE PHARMA Evidence of Budget Accuracy & Reliability 3 Hours of Effort to create the study budget and scenarios in Clinical Maestro 4 Scenarios Built Ranged from $34.9M to $43.1M depending on complexity and service assumptions - 1 2 % Variance between Awarded CRO budget and Clinical Maestro calculated budget CRO Awarded Budget Clinical Maestro $50M $40M $30M $20M $10M $0M Phase 2/3 Therapy Area: O

Join for free to read